Unfortunately, his signature legislation coupled with the Food and Drug Administration's confusing and somewhat disjointed approval process has instead encouraged the off-shoring of business and brought medical discoveries to a halt.
Linking FDA processes and legislation to negative impacts on medical innovation.
Share
More from Michael Burgess
Last night the House Committee on Rules met to report a rule providing for consideration of H.R. 115, the Midnight Rules Relief Act under a closed rule. The rule provides for 1 hour of general debate equally divided between the chair and…
I reserve the balance of my time. Mr. McGOVERN. Mr. Speaker, may I inquire whether the gentleman wants to answer the CBO question or whether he wants me to close?
I thank the gentleman from Georgia for yielding. I rise today to speak in support of the rule and the underlying bills: H.R. 8771, the Department of State, Foreign Operations, and Related Programs Appropriations Act; H.R. 8752, the…
I thank Dr. Bucshon from Indiana for yielding me the time on such an important reauthorization that we are undertaking today. Mr. Speaker, 2018 was the last authorization for sickle cell research. Prior to that, it had been part of the…
Other voices in this conversation
